TG Therapeutics traded at $7.52 this Thursday August 11th, decreasing $0.44 or 5.53 percent since the previous trading session. Looking back, over the last four weeks, TG Therapeutics lost 33.57 percent. Over the last 12 months, its price fell by 66.53 percent. Looking ahead, we forecast TG Therapeutics to be priced at 6.06 by the end of this quarter and at 5.57 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 142.08 1.14 0.81% 22.86%
Amgen 248.35 -3.74 -1.48% 8.85%
Ardelyx 0.89 -0.02 -1.74% -41.17%
Arrowhead Research 45.63 -1.33 -2.83% -23.68%
Bayer 51.68 -0.22 -0.42% 7.75%
Biogen 218.22 -2.82 -1.28% -35.95%
Corcept Therapeutics 27.97 0.23 0.83% 36.17%
Curis 1.07 0.03 2.88% -86.21%
Dynavax Technologies 16.69 -0.57 -3.30% 30.59%
Gilead Sciences 62.45 -0.69 -1.09% -12.24%
Intercept Pharmaceuticals 16.07 -0.63 -3.77% 5.17%
Infinity Pharmaceuticals 1.08 0.05 4.85% -65.50%
J&J 167.14 -3.53 -2.07% -4.60%
Karyopharm Therapeutics 4.96 -0.24 -4.62% 2.90%
Novartis 81.04 -1.47 -1.78% -5.48%
Novavax 40.34 -1.02 -2.47% -83.68%
Puma Biotechnology 3.55 -0.02 -0.56% -51.24%
PTC Therapeutics 52.01 -1.70 -3.17% 30.12%
Regeneron Pharmaceuticals 623.90 -17.59 -2.74% -0.14%
Roche Holding 310.15 -6.80 -2.15% -15.47%
Spectrum Pharmaceuticals 1.21 0.09 8.04% -48.51%
TG Therapeutics 7.52 -0.44 -5.53% -66.53%
Vertex Pharmaceuticals 292.16 -3.61 -1.22% 50.32%
Verastem 1.21 -0.05 -3.97% -57.99%
Ziopharm Oncology 1.78 -0.08 -4.30% -4.81%

Indexes Price Day Year
USND 12780 -74.89 -0.58% -13.74%
US2000 1975 6.01 0.31% -11.98%

TG Therapeutics
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).